Yuvimont AL Tablet SR is a combination medication containing Ambroxol 75mg, Levocetirizine 5mg, and Montelukast 10mg, formulated for the management of respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol, a mucolytic agent, facilitates the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and reducing cough severity. Levocetirizine, a selective second-generation antihistamine, alleviates symptoms associated with allergic reactions such as sneezing, nasal congestion, and itching by inhibiting peripheral histamine H1 receptors without causing significant sedation. Montelukast, a leukotriene receptor antagonist, prevents bronchoconstriction and inflammation by blocking leukotriene D4 receptors in the airways, thus aiding in the control and prevention of asthma symptoms and exercise-induced bronchospasm. The sustained-release formulation ensures prolonged therapeutic effects, enhancing patient compliance by reducing dosing frequency. Yuvimont AL Tablet SR is indicated for patients requiring simultaneous management of mucus hypersecretion, allergic symptoms, and bronchial hyperresponsiveness. It should be used under medical supervision, with caution in patients with hepatic or renal impairment. Adverse effects may include headache, gastrointestinal disturbances, and drowsiness. Consultation with a healthcare professional is recommended prior to initiation of therapy.